Name: CLDI Income Statement - Calidi Biotherapeutics Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

CLDI - Calidi Biotherapeutics, Inc.

USD | NYSE | Healthcare

CLDI Income Statement - Calidi Biotherapeutics Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q3 FY 21	Q2 FY 21
Revenues
Revenues	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses
Research & Development	2.6	2.4	2.4	2.6	2.4	1.8	2.2	2.2	2.7	4.0	3.3	3.2	2.6	-	1.9
Operating Income
Operating Income	(4.2)	(4.5)	(5.0)	(5.7)	(5.1)	(4.0)	(5.2)	(5.8)	(6.8)	(9.8)	(7.2)	(6.5)	(5.4)	(15.3)
Non-Operating
Interest Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.1	0.2
Tax & Net
Income Tax Expense	0.0	(0.0)	0.0	0.0	0.0	0.0	(0.0)	0.0	0.0	(0.0)	0.0	0.0	0.0	0.0	0.0
Per Share
EPS Basic	(0.43)	-	(2.21)	(1.99)	(2.21)	-	(7.75)	(16.75)	(2.03)	-	(1.41)	(14.24)	(0.75)	-	(0.63)	-
Supplementary Data
EBITDA	(3.8)	-	-	-	(4.7)	(2.8)	(5.1)	(5.7)	(6.7)	(9.7)	(7.1)	(6.4)	(5.3)	-	(6.9)	-

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023	FY2022
Revenues
Revenues	-	-	-	-	0.0
Cost of Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
Operating Expenses
Research & Development	9.9	9.7	8.9	13.0	7.3
Selling General & Administrative	9.5	10.5	12.9	16.0	15.9
Selling & Marketing	-
Operating Income
Operating Income	(19.4)	(20.2)	(21.8)	(29.0)	(23.1)
Non-Operating
Interest Income	-	-	-	-	-
Interest Expense	0.0	0.1	0.7	1.1	0.2
Income From Equity Investments	-	-
Tax & Net
Income Tax Expense	0.0	0.0	0.0	0.0	0.0
Net Income From Continuing Ops	(19.1)	(20.1)	(22.2)	(29.2)	(25.4)
Net Income From Discontinued Ops	-
Per Share
EPS Basic	(2.43)	(5.95)	(35.70)	(17.33)	2.99
EPS Diluted	(2.43)	(5.95)	(35.70)	(17.33)	2.99
Shares Basic	10.3	0.0
Supplementary Data
EBITDA	-	(18.6)	(20.2)	(28.6)	(22.9)
EBIT	(19.4)	(20.2)	(21.8)	(29.0)	(23.1)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)